SwePub
Sök i SwePub databas

  Extended search

Träfflista för sökning "WFRF:(Hernandez Vicent) "

Search: WFRF:(Hernandez Vicent)

  • Result 1-6 of 6
Sort/group result
   
EnumerationReferenceCoverFind
1.
  • Zamora, Juan Carlos, et al. (author)
  • Considerations and consequences of allowing DNA sequence data as types of fungal taxa
  • 2018
  • In: IMA Fungus. - : INT MYCOLOGICAL ASSOC. - 2210-6340 .- 2210-6359. ; 9:1, s. 167-185
  • Journal article (peer-reviewed)abstract
    • Nomenclatural type definitions are one of the most important concepts in biological nomenclature. Being physical objects that can be re-studied by other researchers, types permanently link taxonomy (an artificial agreement to classify biological diversity) with nomenclature (an artificial agreement to name biological diversity). Two proposals to amend the International Code of Nomenclature for algae, fungi, and plants (ICN), allowing DNA sequences alone (of any region and extent) to serve as types of taxon names for voucherless fungi (mainly putative taxa from environmental DNA sequences), have been submitted to be voted on at the 11th International Mycological Congress (Puerto Rico, July 2018). We consider various genetic processes affecting the distribution of alleles among taxa and find that alleles may not consistently and uniquely represent the species within which they are contained. Should the proposals be accepted, the meaning of nomenclatural types would change in a fundamental way from physical objects as sources of data to the data themselves. Such changes are conducive to irreproducible science, the potential typification on artefactual data, and massive creation of names with low information content, ultimately causing nomenclatural instability and unnecessary work for future researchers that would stall future explorations of fungal diversity. We conclude that the acceptance of DNA sequences alone as types of names of taxa, under the terms used in the current proposals, is unnecessary and would not solve the problem of naming putative taxa known only from DNA sequences in a scientifically defensible way. As an alternative, we highlight the use of formulas for naming putative taxa (candidate taxa) that do not require any modification of the ICN.
  •  
2.
  • Burisch, Johan, et al. (author)
  • Initial Disease Course and Treatment in an Inflammatory Bowel Disease Inception Cohort in Europe : The ECCO-EpiCom Cohort
  • 2014
  • In: Inflammatory Bowel Diseases. - : Lippincott Williams & Wilkins. - 1078-0998 .- 1536-4844. ; 20:1, s. 36-46
  • Journal article (peer-reviewed)abstract
    • Background:The EpiCom cohort is a prospective, population-based, inception cohort of inflammatory bowel disease (IBD) patients from 31 European centers covering a background population of 10.1 million. The aim of this study was to assess the 1-year outcome in the EpiCom cohort.Methods:Patients were followed-up every third month during the first 12 (3) months, and clinical data, demographics, disease activity, medical therapy, surgery, cancers, and deaths were collected and entered in a Web-based database (www.epicom-ecco.eu).Results:In total, 1367 patients were included in the 1-year follow-up. In western Europe, 65 Crohn's disease (CD) (16%), 20 ulcerative colitis (UC) (4%), and 4 IBD unclassified (4%) patients underwent surgery, and in eastern Europe, 12 CD (12%) and 2 UC (1%) patients underwent surgery. Eighty-one CD (20%), 80 UC (14%), and 13 (9%) IBD unclassified patients were hospitalized in western Europe compared with 17 CD (16%) and 12 UC (8%) patients in eastern Europe. The cumulative probability of receiving immunomodulators was 57% for CD in western (median time to treatment 2 months) and 44% (1 month) in eastern Europe, and 21% (5 months) and 5% (6 months) for biological therapy, respectively. For UC patients, the cumulative probability was 22% (4 months) and 15% (3 months) for immunomodulators and 6% (3 months) and 1% (12 months) for biological therapy, respectively in the western and eastern Europe.Discussion:In this cohort, immunological therapy was initiated within the first months of disease. Surgery and hospitalization rates did not differ between patients from eastern and western Europe, although more western European patients received biological agents and were comparable to previous population-based inception cohorts.
  •  
3.
  •  
4.
  • Burisch, Johan, et al. (author)
  • Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort-An Epi-IBD Study
  • 2019
  • In: Journal of Crohn's & Colitis. - : Oxford University Press. - 1873-9946 .- 1876-4479. ; 13:2, s. 198-208
  • Journal article (peer-reviewed)abstract
    • Background and Aims: Few population-based cohort studies have assessed the disease course of ulcerative colitis [UC] in the era of biological therapy and widespread use of immunomodulators. The aim of this study was to assess the 5-year outcome and disease course of patients with UC in the Epi-IBD cohort.Methods: In a prospective, population-based inception cohort of unselected patients with UC, patients were followed up from the time of their diagnosis, which included the collection of their clinical data, demographics, disease activity, medical therapy, and rates of surgery, cancers, and deaths. Associations between outcomes and multiple covariates were analysed by Cox regression analysis.Results: A total of 717 patients were included in the study. During follow-up, 43 [6%] patients underwent a colectomy and 163 [23%] patients were hospitalised. Of patients with limited colitis [distal to the left flexure], 90 [21%] progressed to extensive colitis. In addition, 92 [27%] patients with extensive colitis experienced a regression in disease extent, which was associated with a reduced risk of hospitalisation (hazard ratio [HR]: 0.5 95% CI: 0.3-0.8]. Overall, patients were treated similarly in both geographical regions; 80 [11%] patients needed biological therapy and 210 [29%] patients received immunomodulators. Treatment with immunomodulators was found to reduce the risk of hospitalisation [HR: 0.5 95% CI: 0.3-0.8].Conclusions: Although patients in this population-based cohort were treated more aggressively with immunomodulators and biological therapy than in cohorts from the previous two decades, their disease outcomes, including colectomy rates, were no different. However, treatment with immunomodulators was found to reduce the risk of hospitalisation.
  •  
5.
  •  
6.
  • Pino-Chamorro, Jose Ángel, et al. (author)
  • Mechanism of [3+2] Cycloaddition of Alkynes to the [Mo3S4(acac)(3)(py)(3)][PF6] Cluster
  • 2015
  • In: Chemistry - A European Journal. - : Wiley-VCH Verlagsgesellschaft. - 0947-6539 .- 1521-3765. ; 21:7, s. 2835-2844
  • Journal article (peer-reviewed)abstract
    • A study, involving kinetic measurements on the stopped-flow and conventional UV/Vis timescales, ESI-MS, NMR spectroscopy and DFT calculations, has been carried out to understand the mechanism of the reaction of [Mo3S4(acac)(3)(py)(3)][PF6] ([1]PF6; acac = acetylacetonate, py = pyridine) with two RC equivalent to CR alkynes (R = CH2OH (btd), COOH (adc)) in CH3CN. Both reactions show polyphasic kinetics, but experimental and computational data indicate that alkyne activation occurs in a single kinetic step through a concerted mechanism similar to that of organic [3+2] cycloaddition reactions, in this case through the interaction with one Mo(mu-S)(2) moiety of [1](+). The rate of this step is three orders of magnitude faster for adc than that for btd, and the products initially formed evolve in subsequent steps into compounds that result from substitution of py ligands or from reorganization to give species with different structures. Activation strain analysis of the [3+2] cycloaddition step reveals that the deformation of the two reactants has a small contribution to the difference in the computed activation barriers, which is mainly associated with the change in the extent of their interaction at the transition-state structures. Subsequent frontier molecular orbital analysis shows that the carboxylic acid substituents on adc stabilize its HOMO and LUMO orbitals with respect to those on btd due to better electron-withdrawing properties. As a result, the frontier molecular orbitals of the cluster and alkyne become closer in energy; this allows a stronger interaction.
  •  
Skapa referenser, mejla, bekava och länka
  • Result 1-6 of 6
Type of publication
journal article (6)
Type of content
peer-reviewed (5)
other academic/artistic (1)
Author/Editor
Burisch, Johan (4)
Magro, Fernando (4)
Halfvarson, Jonas, 1 ... (4)
Andersen, Vibeke (4)
Almer, Sven (3)
Larsson, Ellen, 1961 (1)
show more...
Svantesson, Sten (1)
Kõljalg, Urmas (1)
Saar, Irja (1)
Ghobad-Nejhad, Masoo ... (1)
Pawlowska, Julia (1)
Suija, Ave (1)
Peintner, Ursula (1)
Borovicka, Jan (1)
Ellul, Pierre (1)
Svensson, Måns (1)
Nagy, István (1)
Tibell, Leif (1)
Thor, Göran (1)
Ahti, Teuvo (1)
Mayrhofer, Helmut (1)
Kärnefelt, Ingvar (1)
Thell, Arne (1)
Moberg, Roland (1)
Chen, Jie (1)
De Kesel, André (1)
Bjornsson, Einar (1)
Eriksson, Carl, 1981 ... (1)
Ryman, Svengunnar (1)
Algarra, Andres G. (1)
Læssøe, Thomas (1)
Kukwa, Martin (1)
Grube, Martin (1)
Aptroot, Andre (1)
Zhulina, Yaroslava, ... (1)
Tuovinen, Veera (1)
Spribille, Toby (1)
Miller, Andrew N. (1)
Hallenberg, Nils, 19 ... (1)
Košuthová, Alica (1)
Knudsen, Kerry (1)
Wedin, Mats, 1963- (1)
Westberg, Martin (1)
Buyck, Bart (1)
Jayawardena, Ruvishi ... (1)
Phukhamsakda, Chayan ... (1)
Zhang, Huang (1)
Réblová, Martina (1)
Fournier, Jacques (1)
Diederich, Paul (1)
show less...
University
Örebro University (4)
University of Gothenburg (1)
Uppsala University (1)
Stockholm University (1)
Lund University (1)
Karolinska Institutet (1)
show more...
Swedish Museum of Natural History (1)
Swedish University of Agricultural Sciences (1)
show less...
Language
English (6)
Research subject (UKÄ/SCB)
Medical and Health Sciences (4)
Natural sciences (2)

Year

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view